Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Respironics Awakens In April; Strong Sales Spark 13% Stock Price Gain

This article was originally published in The Gray Sheet

Executive Summary

Respironics' third-quarter results awakened Wall Street to the fact that the sleep-disorder equipment manufacturer had shrugged off its recent reimbursement difficulties. The company's stock price was up 13%, or 1-7/8, in April, closing the month at 16-1/4.

You may also be interested in...



Respironics Investors Breathing Easy After Turnaround; Stock Up 25% In Nov.

An accelerating growth rate and positive news highlighted at Respironics' Nov. 16 annual shareholder meeting breathed new life into the company's stock price. The issue closed Nov. 30 at $24.56, up $4.93, or 25.1%, for the month.

Respironics Investors Breathing Easy After Turnaround; Stock Up 25% In Nov.

An accelerating growth rate and positive news highlighted at Respironics' Nov. 16 annual shareholder meeting breathed new life into the company's stock price. The issue closed Nov. 30 at $24.56, up $4.93, or 25.1%, for the month.

Itamar Pursuing Sleep Apnea As First Application Of PAT Platform

Respironics will distribute Itamar Medical's peripheral arterial tonometry technology (PAT) with its sleep monitoring instruments to assist in the diagnosis of sleep apnea.

Related Content

UsernamePublicRestriction

Register

MT013345

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel